Pharming Group

-2.07% €0.85

17:30 – 15/05/2024

Nieuws van Pharming Group

Ondanks omzetstijging verliest Pharming op de beurs

Bron: Www.bnr.nl

Autheur: Jorn Lucas

Gepubliceerd op: 2024-05-08

Het Nederlandse biotech- en farmabedrijf Pharming heeft afgelopen kwartaal de omzet, op jaarbasis, met 31 procent zijn stijgen naar ruim 55 miljoen dollar. Het bedrijf uit Leiden schrijft de groei toe aan de lancering van zijn nieuwe medicijn Joenja in de Ver…

Pharming N : Pharming Group announces the placement of €100 million convertible bonds due 2029

Bron: Marketscreener.com

Gepubliceerd op: 2024-04-19

(marketscreener.com) Pharming Group N.V. Pharming Group N.V. Below you will find information from the register publication of inside information. The information has been provided by the organisation. Registration date18 apr 2024 – 18:38 …

Pharming N : Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Bron: Marketscreener.com

Gepubliceerd op: 2024-04-24

(marketscreener.com) Pharming Group N.V. Pharming Group N.V. Below you will find information from the register publication of inside information. The information has been provided by the organisation. Registration date24 apr 2024 – 07:00 …

Pharming Group (NASDAQ:PHAR) to Post Q3 2024 Earnings of $0.01 Per Share, HC Wainwright Forecasts

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-05-10

Pharming Group (NASDAQ:PHAR – Free Report) – Equities researchers at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for Pharming Group in a research report issued to clients and investors on Wednesday, May 8th. HC Wainwright analyst J. …

Pharming Group to report first quarter 2024 financial results on May 8

Bron: GlobeNewswire

Autheur: Pharming Group N.V.

Gepubliceerd op: 2024-04-24

Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 20…

Pharming Group’s Strategic Financial Maneuver

Bron: Biztoc.com

Autheur: tipranks.com

Gepubliceerd op: 2024-04-25

has released an update. Pharming Group N.V. has announced the launch of a new €100 million convertible bond offering due 2… #pharminggroupnv

Pharming Group to Post FY2025 Earnings of $0.07 Per Share, HC Wainwright Forecasts (NASDAQ:PHAR)

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-05-14

Pharming Group (NASDAQ:PHAR – Free Report) – Analysts at HC Wainwright upped their FY2025 earnings per share estimates for Pharming Group in a note issued to investors on Wednesday, May 8th. HC Wainwright analyst J. Pantginis now forecasts that the company wi…

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Bron: Marketscreener.com

Gepubliceerd op: 2024-04-24

(marketscreener.com) Recognition given for achievement in commercializing Joenja® , a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. is pleas…

Pharming Group (NASDAQ:PHAR) Hits New 1-Year Low at $9.35

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-04-20

Pharming Group (NASDAQ:PHAR – Get Free Report)’s stock price hit a new 52-week low on Thursday . The stock traded as low as $9.35 and last traded at $9.35, with a volume of 665 shares trading hands. The stock had previously closed at $10.17. Wall Street Analy…

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Bron: Marketscreener.com

Gepubliceerd op: 2024-04-18

(marketscreener.com) NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group N.V. launches new convertibl…

Pharming Group to report first quarter 2024 financial results on May 8

Bron: Marketscreener.com

Gepubliceerd op: 2024-04-24

(marketscreener.com) Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. confirms it will report its preliminary first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for ana…

Pharming Group (PHAR) Scheduled to Post Quarterly Earnings on Wednesday

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-05-06

Pharming Group (NASDAQ:PHAR – Get Free Report) is scheduled to announce its earnings results before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.01 per share for the quarter. Pharming Group (NASDAQ:PHAR – Get …

Pharming Group reports first quarter 2024 financial results and provides business update

Bron: Investing.com

Autheur: Investing.com

Gepubliceerd op: 2024-05-08

Pharming Group reports first quarter 2024 financial results and provides business update

Pharming Group reports first quarter 2024 financial results and provides business update

Bron: Investing.com

Autheur: Investing.com

Gepubliceerd op: 2024-05-08

Pharming Group reports first quarter 2024 financial results and provides business update

Pharming Group announces the placement of €100 million convertible bonds due 2029

Bron: Marketscreener.com

Gepubliceerd op: 2024-04-18

(marketscreener.com) NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 18th April, 2024: …

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Bron: Marketscreener.com

Gepubliceerd op: 2024-04-19

(marketscreener.com) NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 19th April, 2024: …

Pharming Group reports first quarter 2024 financial results and provides business update

Bron: Marketscreener.com

Gepubliceerd op: 2024-05-08

(marketscreener.com) Primary immunodeficiencies beyond APDS Pharming plans an initial Phase II, proof of concept, clinical trial in targeted PID genetic disorders with immune dysregulation linked to PI3Kẟ signaling in lymphocytes, with similar clinical phenot…

Pharming N : Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 – Form 6-K

Bron: Marketscreener.com

Gepubliceerd op: 2024-04-25

(marketscreener.com) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE…https://www.marketscreener…

Pharming N : 1Q 2024 Financial Results Presentation – May 8, 2024

Bron: Marketscreener.com

Gepubliceerd op: 2024-05-08

(marketscreener.com) first and only FDA approved treatment for APDS – U.S. launch April 2023 Revenue FY23 US$18.2M 1Q24 US$9.6M Strong focus on patient finding Israel approval Regulatory reviews ongoing in EUR, U.K., CAN, AUS…https://ww…

Pharming Group Lauded for Rare Disease Treatment

Bron: Biztoc.com

Autheur: tipranks.com

Gepubliceerd op: 2024-04-24

has released an update. Pharming Group N.V. has been recognized as an Industry Innovator at the National Organization for … #pharminggroupnv #nationalorganization

Pharming Group reports first quarter 2024 financial results and provides business update

Bron: Investing.com

Autheur: Investing.com

Gepubliceerd op: 2024-05-08

Pharming Group reports first quarter 2024 financial results and provides business update

Earnings call: Pharming Group reports strong Q1 growth, eyes global expansion

Bron: Investing.com

Autheur: Investing.com

Gepubliceerd op: 2024-05-13

Earnings call: Pharming Group reports strong Q1 growth, eyes global expansion

Pharming N : to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards – Form 6-K

Bron: Marketscreener.com

Gepubliceerd op: 2024-04-24

(marketscreener.com) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE…https://www.marketscreener…

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Bron: GlobeNewswire

Autheur: Pharming Group N.V.

Gepubliceerd op: 2024-04-24

Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized

PHAR Stock Earnings: Pharming Reported Results for Q1 2024

Bron: Biztoc.com

Autheur: investorplace.com

Gepubliceerd op: 2024-05-08

Pharming (NASDAQ: ) just reported results for the first quarter of 2024. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnin…

Pharming Group announces the placement of €100 million convertible bonds due 2029

Bron: GlobeNewswire

Autheur: Pharming Group N.V.

Gepubliceerd op: 2024-04-18

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Bron: GlobeNewswire

Autheur: Pharming Group N.V.

Gepubliceerd op: 2024-04-19

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Bron: GlobeNewswire

Autheur: Pharming Group N.V.

Gepubliceerd op: 2024-04-18

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.

Introducing the NetBeacon Institute: Empowering a Safer Web

Bron: PR Newswire UK

Gepubliceerd op: 2024-05-06

DNS Abuse Institute announces renaming to coincide with an expansion of its offerings in an effort to eliminate DNS Abuse online RESTON, Va., May 6, 2024 /PRNewswire/ — The DNS Abuse Institute, dedicated to combating online technical abuse and fostering a sa…

Recombinant Proteins Market Surges to USD 6.47 Billion by 2031, Propelled by 8% CAGR – Verified Market Research®

Bron: GlobeNewswire

Autheur: Verified Market Research

Gepubliceerd op: 2024-05-13

The demand for biopharmaceuticals and improvements in genetic engineering techniques are driving the growth of the Recombinant Proteins Market, as they enable efficient protein manufacturing. Nevertheless, the progress of genetic modification is hindered by t…

Cyber Security Specialist

Bron: Corriere.it

Gepubliceerd op: 2024-05-13

Trova lavoro come Cyber Security Specialist Tutta Italia. Questo annuncio di lavoro e tutte le altre posizioni aperte nel settore Elettrotecnica, metalmeccanico su Trovolavoro

How Does Fraud Detection Using AI Work?

Bron: Vmblog.com

Autheur: David

Gepubliceerd op: 2024-05-10

Why is fraud detection using AI a great idea, and how does it work? Find out here.

Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice

Bron: Plos.org

Autheur: Martha M. O’Kennedy, Robyn Roth, Karen Ebersohn, Lissinda H. du Plessis, Sipho Mamputha, Daria A. Rutkowska, Ilse du Preez, Jan A. Verschoor, Yolandy Lemmer

Gepubliceerd op: 2024-04-16

A safe, highly immunogenic multivalent vaccine to protect against all nine serotypes of African horse sickness virus (AHSV), will revolutionise the AHS vaccine industry in endemic countries and beyond. Plant-produced AHS virus-like particles (VLPs) and solubl…

Scroll naar boven